U.S. stock market midday update: Nasus Pharma plummets 12.57%, trading volume surges, market volatility draws attention

U.S. Stock Market Midday Update Nasus Pharma, down 12.57%, with increased trading volume and no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry Eli Lilly down 0.17%, with increased trading volume. Based on recent key news: On January 2, Celltrion signed a $473 million production contract with Eli Lilly, promoting the expansion of Eli Lilly's collaboration in the biopharmaceutical field. This move may enhance Eli Lilly's production capacity and market competitiveness. On December 31, analysts expect Eli Lilly's sales to grow by 20% by 2026, mainly driven by the diabetes drug Mounjaro and the obesity drug Zepbound. This expected growth may boost investor confidence. On December 31, Eli Lilly was listed as one of the best pharmaceutical stocks for 2026, showing market confidence in its future growth potential. The weight loss drug market is highly competitive, with Eli Lilly holding a dominant position. Johnson & Johnson down 0.31%, with increased trading volume. Based on recent news: On January 2, Johnson & Johnson announced a first-quarter dividend of $1.30 per share for 2026, unchanged from the previous one. This news indicates the company's financial stability but failed to excite the market, leading to a slight decline in stock price. On December 30, Johnson & Johnson failed to transfer its talc powder litigation cases to bankruptcy proceedings, causing ovarian cancer claims to become active nationwide. This legal risk increases uncertainty for investors, affecting stock performance. On January 1, analysts pointed out that Johnson & Johnson performed strongly in technical momentum and fundamental indicators, but due to being close to a 52-week high and a relatively high Relative Strength Index (RSI), there is sensitivity to a pullback. Investors need to closely monitor the upcoming earnings report and competitive dynamics. High-dividend stocks are in focus, as the market demands stable cash returns. Pfizer up 1.10%. Based on recent news: On January 1, U.S. pharmaceutical companies plan to raise prices on over 350 drugs, with Pfizer announcing price increases on about 80 drugs, including cancer drug Ibrance, migraine drug Nurtec, and COVID-19 treatment drug Paxlovid, with increases below 10%, but the COVID-19 vaccine Comirnaty rising by 15%. This move shows the pharmaceutical market's insistence on price adjustments, driving Pfizer's stock price up. Source: Reuters On January 1, despite facing price reduction pressures from the Trump administration, Pfizer and GlaxoSmithKline's drug price increases reached 4% and 2% to 8.9%, further exacerbating the economic burden on U.S. patients. This news enhances market confidence in Pfizer's future profitability, driving the stock price up. Source: Reuters On January 1, major U.S. indices opened lower on Christmas Eve, showing increased market concerns about high valuations, leading investors to turn to defensive stocks like pharmaceutical companies, benefiting Pfizer Source: Reuters Drug prices rise, market worries about high valuations Stocks ranked among the top in industry market capitalization AstraZeneca fell 0.40%. There has been no significant news regarding AstraZeneca recently; trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no_news